Original title: It’s set! The Shanghai-Shenzhen-Hong Kong Stock Connect target list expansion is the first time Sci-tech Innovation Board shares are included in the Hong Kong-listed biotech company. When can they be purchased?
Boots fall,Shanghai-Shenzhen-Hong Kong Stock ConnectinvestmentThe topic is more varied.
On November 27, the Shanghai and Shenzhen exchanges said that, in order to further improve the interconnection mechanism, the Shanghai, Shenzhen and Hong Kong exchanges reached a consensus on measures to simultaneously expand the scope of the Shanghai Stock Connect. Shenzhen-Hong Kong. between them,Committee for Scientific and Technological InnovationThe stock will be included in the Shanghai-Shenzhen-Hong Kong Stock Connect perimeter.
It is understood that the Shanghai, Shenzhen and Hong Kong stock exchanges will advance the relevant business technical preparationsworks, Is expected to be completed in early 2021marketAfter the preparatory work, the above-mentioned scientific and technological innovation committee actions will be included in the scope of the Shanghai-Shenzhen-Hong Kong Stock Connect actions.
Same day,adIt is also said that biotechnology listed in Hong Kongthe companyIt will be includedSouth direct tradeThe scope of the goal. Mainland investors will be able to invest in Hong Kong’s equity biotechnology sector.
Northbound funds may be “wiped out” next year for the goals of the council for scientific and technological innovation
On November 27, the Shanghai and Shenzhen stock exchanges jointly announced that the scope of the Shanghai-Shenzhen-Hong Kong Stock Connect will be expanded.
Previously, the three exchanges in Shanghai, Shenzhen and Hong Kong reached a consensus on the agreement to include the A + H shares of companies listed on the Sci-tech Innovation Board under the Shanghai-Shenzhen-Hong Kong Stock Connect Recently, the three exchanges have further negotiated and decided that the shares of the SSE STAR market belong to the SSE 180 and SSE 380 indices.Constituent stocksOr A shares of the A + H joint stock company, the shares will be transferred under the existing Shanghai-Hong Kong Stock Connect regulationsShanghai Stock ConnectFor the scope of the shares, the corresponding H shares will be transferred to the Southbound Stock Connect scope in accordance with existing Shanghai-Shenzhen-Hong Kong Stock Connect regulations.
On the same day, the Shanghai Stock Exchange and China Securities Index Co., Ltd. announced that they would be adjusting the samples of SSE 180, SSE 380 and other indices. The adjustment took effect on 14 December. At that time, the Shanghai Stock Exchange 180,CSI 300Stocks from the Sci-tech Innovation Board are expected to appear on an equal scale index for the first time.
From the list,China Micro CompanyIt will be transferred to the Shanghai 180 index sample.Retron Micron、Hangke technology、Lanqi technology、Anji Technology、Western superconductor、Haier BioA total of 6 stocks of the scientific and technological innovation council will be transferred to the Shanghai 380 index.
The Shanghai Stock Exchange said that to further improve the scientific and technological innovation boardInfluenceBy introducing more medium- and long-term funds and providing investment channels for small and medium-sized investors, it is imperative that the stocks of the Scientific and Technological Innovation Board be included in the constituent indices.
The Shanghai Stock Exchange also stated that the broad domestic and foreign marketsResearchInstitutional investors have been shown to positively affirm the inclusion of SSE Securities in SSE 180, CSI 300 and other component indicesattitude。
It should be noted that, considering the implementation of investor eligibility management in the Sci-tech Innovation Board, investors who buy and sell Sci-Tech Innovation Board shares through Shanghai Stock Connect are bound to be limited to professional institutional investors defined in compliance with relevant Hong Kong rules. The exchange said the relevant regulations are subject to approval by regulators in both places.
In the next phase, the Shanghai, Shenzhen and Hong Kong stock exchanges will actively promote the relevant business and technical preparations. The shares of the sci-tech innovation council in question are expected to be included under the Shanghai-Shenzhen-Hong Kong Stock Connect after completion of market preparations in early 2021.
The Hong Kong-based biotech company becomes a new target a month later
At the same time, the three exchanges of Shanghai, Shenzhen and Hong Kong agreed that theMain board listIf the shares of a biotech company listed in Chapter 18A of the Rules are constituent shares of the relevant Hang Seng Composite Index or the H shares of an A + H listed company listed on the Shanghai, Shenzhen and Hong Kong Stock Exchanges, the shares will be based on the ‘current Regulations to be transferred to the scope of Southbound Stock Connect shares (Biotech company shares belonging to H shares of A + H joint stock company on the Sci-tech Innovation Board will be transferred under Southbound Stock Connect according to the above-mentioned agreements to include shares of the STAR Board).
The market has been waiting for the expansion of the target for some time. On November 25, Hong Kong Special Administrative Region Chief Executive Carrie Lam announced the fourth incumbent policyrelationshipShi said the central government continues to support Hong Kong for consolidation and upgradingInternational financeCentral status, as well as accelerating the implementation of the “cross-borderFinancial managementIt also agreed to include Hong Kong-listed unprofitable biotech companies in the new listing system and Continental Science and Technology Innovation Board shares in the “Connectivity” stock selection under certain conditions.
Previously, the Hong Kong Stock Exchange AdministrationPresidentLi Xiaojia once pointed out that Hong Kong stocks could become the world’s largest biotech IPO market in the future. PricewaterhouseCoopers said the new economy and biotechnologyenterpriseIt will become the second half of 2020Hong Kong Stock ExchangeThe main driving force behind the listing activities is that more than 10 biotech companies are expected to be successfully listed on the Hong Kong Stock Exchange throughout 2020. As part of the interconnection mechanism, Hong Kong’s equity biotechnology goals should favor investors of mainland China.
It is understood that the Shanghai, Shenzhen and Hong Kong Stock Exchange will actively promote the completion of preparations for the relevant markets in the next phase. Shares of the aforementioned biotech companies are expected to be included in the scope of Southbound Stock Connect shares one month after the announcement on the 27th. Biotech companies that do not have the “B” logo at the end of the stock name and are already shares Southbound at the time of this announcement will not be affected.
The exchange said that in the future the three exchanges of Shanghai, Shenzhen and Hong Kong will continue to cooperate closely, continue to optimize the interconnection mechanism and promote the coordinated, stable and healthy development of the capital markets of the two places.
(Responsible publisher: DF380)
Solemnly declares: the purpose of this information is to disseminate more information, and it has nothing to do with this stand.